Posted by Michael Wonder on 07 Feb 2020
AbbVie's Skyrizi now publicly reimbursed in Ontario, Alberta, Saskatchewan and Quebec for the treatment of moderate to severe plaque psoriasis
6 February 2020 - Skyrizi is the only IL-23 inhibitor to arrive at a positive conclusion with the pCPA and is currently listed on the provincial formularies of Ontario, Alberta, Saskatchewan and Quebec.
AbbVie announced today that Ontario, Alberta, Saskatchewan and Quebec have listed Skyrizi (risankizumab) on their respective provincial formularies for the treatment of moderate to severe plaque psoriasis.
This announcement comes just two months after AbbVie successfully reached an agreement with the pan-Canadian Pharmaceutical Alliance – bringing a much-needed treatment to patients living with psoriasis.
